AtriCure Reports Q3 Earnings Beat with Revenue Growth of 15.1%
AtriCure (ATRC) reported third-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted a Non-GAAP earnings per share (EPS) of $0.18, outperforming estimates by $0.17, while revenue reached $154.5 million, representing a 15.1% increase year-over-year and beating projections by $3.31 million. Looking ahead, management has provided updated guidance for the full year 2026, projecting total revenue to fall between approximately $606 million and $610 million. This upward momentum reflects steady growth in the company's medical device operations.
Tickers: $ATRC